000274483 001__ 274483
000274483 005__ 20240229154935.0
000274483 0247_ $$2doi$$a10.3390/cimb45030136
000274483 0247_ $$2pmid$$apmid:36975506
000274483 0247_ $$2ISSN$$a1467-3037
000274483 0247_ $$2ISSN$$a1467-3045
000274483 0247_ $$2altmetric$$aaltmetric:144542094
000274483 037__ $$aDKFZ-2023-00626
000274483 041__ $$aEnglish
000274483 082__ $$a570
000274483 1001_ $$aKruchen, Anne$$b0
000274483 245__ $$aEpigenetic Modification of Mesenchymal Stromal Cells Derived from Bone Marrow and Embryonal Tumors to Facilitate Immunotherapeutic Approaches in Pediatric Malignancies.
000274483 260__ $$aWymondham, Norfolk$$c2023
000274483 3367_ $$2DRIVER$$aarticle
000274483 3367_ $$2DataCite$$aOutput Types/Journal article
000274483 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1680078911_16640
000274483 3367_ $$2BibTeX$$aARTICLE
000274483 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274483 3367_ $$00$$2EndNote$$aJournal Article
000274483 520__ $$aMesenchymal stromal cells (MSC) are part of the bone marrow architecture and contribute to the homeostasis of hematopoietic stem cells. Moreover, they are known to regulate immune effector cells. These properties of MSC are pivotal under physiologic conditions, and they may aberrantly also protect malignant cells. MSCs are also found in the leukemic stem cell niche of the bone marrow and as part of the tumor microenvironment. Here, they protect malignant cells from chemotherapeutic drugs and from immune effector cells in immunotherapeutic approaches. Modulation of these mechanisms may improve the efficacy of therapeutic regimens. We investigated the effect of the histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA, Vorinostat™) on the immunomodulatory effect and cytokine profile of MSC derived from bone marrow and pediatric tumors. The immune phenotype of MSC was not markedly affected. SAHA-treated MSC showed reduced immunomodulatory effects on T cell proliferation and NK cell cytotoxicity. This effect was accompanied by an altered cytokine profile of MSC. While untreated MSC inhibited the production of certain pro-inflammatory cytokines, SAHA treatment led to a partial increase in IFNγ and TNFα secretion. These alterations of the immunosuppressive milieu might be beneficial for immunotherapeutic approaches.
000274483 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000274483 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000274483 650_7 $$2Other$$ahistone deacetylase inhibitor
000274483 650_7 $$2Other$$aleukemic stem cell niche
000274483 650_7 $$2Other$$amesenchymal stromal cells
000274483 650_7 $$2Other$$atumor microenvironment
000274483 7001_ $$0P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8$$aJohann, Pascal$$b1$$udkfz
000274483 7001_ $$aRekowski, Laura$$b2
000274483 7001_ $$00000-0002-7477-6632$$aMüller, Ingo$$b3
000274483 773__ $$0PERI:(DE-600)2090836-2$$a10.3390/cimb45030136$$gVol. 45, no. 3, p. 2121 - 2135$$n3$$p2121 - 2135$$tCurrent issues in molecular biology$$v45$$x1467-3037$$y2023
000274483 909CO $$ooai:inrepo02.dkfz.de:274483$$pVDB
000274483 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000274483 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000274483 9141_ $$y2023
000274483 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-07T10:13:34Z
000274483 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-03-28
000274483 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-03-28
000274483 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-03-28
000274483 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-03-28
000274483 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-18
000274483 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-18
000274483 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-18
000274483 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-18
000274483 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000274483 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000274483 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000274483 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:57:17Z
000274483 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:57:17Z
000274483 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:57:17Z
000274483 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000274483 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000274483 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000274483 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2023-10-24
000274483 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCURR ISSUES MOL BIOL : 2022$$d2023-10-24
000274483 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-24
000274483 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000274483 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000274483 980__ $$ajournal
000274483 980__ $$aVDB
000274483 980__ $$aI:(DE-He78)B062-20160331
000274483 980__ $$aI:(DE-He78)HD01-20160331
000274483 980__ $$aUNRESTRICTED